SCHEMBL4917296

SCHEMBL4917296

CS(=O)(=O)Nc1cccc(Nc2nc(NCc3ccccc3CCO)c3cc[nH]c3n2)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTK2 Q05397 8/20 0.51
CLK4 Q9HAZ1 3/20 0.45
CLK2 P49760 1/20 0.45
AURKB Q96GD4 1/20 0.45
JAK2 O60674 3/20 0.44
BRD4 O60885 3/20 0.44
USP2 O75604 3/20 0.42
CYP1A2 P05177 3/20 0.42
CYP3A4 P08684 3/20 0.42
CYP2D6 P10635 3/20 0.42
TSHR P16473 3/20 0.42
MEN1 O00255 2/20 0.42
ALDH1A1 P00352 2/20 0.42
LMNA P02545 2/20 0.42
TP53 P04637 2/20 0.42
CYP2C19 P33261 2/20 0.42
KMT2A Q03164 2/20 0.42
CYP2C9 P11712 2/20 0.42
JAK1 P23458 2/20 0.40
NTRK1 P04629 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4696226 0.85 PTK2 (0.45) PTK2CLK4USP2CYP1A2CYP3A4
SCHEMBL4918495 0.78 JAK2 (0.46) PTK2CLK4CLK2AURKBJAK2
SCHEMBL4916831 0.78 PTK2 (0.44) PTK2CLK4AURKBUSP2CYP1A2
SCHEMBL4919419 0.77 JAK2 (0.46) PTK2JAK2BRD4CYP1A2CYP3A4
SCHEMBL4920915 0.77 JAK2 (0.50) PTK2JAK2BRD4JAK1
SCHEMBL4914873 0.75 PAK4 (0.63) CLK4JAK2BRD4USP2CYP1A2
SCHEMBL4650409 0.74 PTK2 (0.51) PTK2JAK2BRD4JAK1
SCHEMBL4915798 0.74 JAK1 (0.41) PTK2AURKBJAK2BRD4JAK1
SCHEMBL4908846 0.74 PTK2 (0.44) PTK2CLK4JAK2USP2CYP1A2
SCHEMBL4909586 0.74 JAK2 (0.59) PTK2CLK4JAK2BRD4USP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080261973-A1 Sulphonamidoaniline Derivatives Being Janus Kinase Inhibitors NOVARTIS AG (CH) 2008-10-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080261973-A1 Sulphonamidoaniline Derivatives Being Janus Kinase Inhibitors GRK4, JAK2, ALK PTK2 1036/4885CLK4 666/4885CLK2 1911/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.